Advertisement

An Investigation of the Metabolism of Tay-Sachs Ganglioside Specifically Labeled in Critical Portions of the Molecule

  • R. O. Brady
  • J. F. Tallman
  • W. G. Johnson
  • J. M. Quirk
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 19)

Abstract

Investigations which provided for a demonstration of an enzymatic deficiency in Tay-Sachs disease varied considerably in design from the basic pattern of experimentation which proved so useful for unravelling the metabolic abnormalities in related disorders of lipid metabolism. For example, in order to elucidate the etiology of Gaucher’s disease, Niemann-Pick disease, and Fabry’s disease, the principal sphingolipid which accumulates in the tissues of patients with these disorders was labeled with radiocarbon-14C or radiohydrogen-3H in a critical portion of the molecule. The metabolism of these labeled compounds was then examined in the following fashion. Enzymes which catalyzed the initial step in the catabolism of the accumulating substances were identified and partially purified from appropriate mammalian tissues. The conditions which influenced the activity of these enzymes were ascertained. The optimal pH for the reactions was determined, the Michaelis constant for each enzyme was defined, and the products of the reactions were identified. When these parameters were clearly established in control human tissue preparations, the activity of the enzyme suspected of being involved in the pathogenesis of the disease was determined in similar specimens obtained from patients with these disorders of lipid metabolism. This technique was used with success for identifying the deficiency of glucocerebrosidase in Gaucher’s disease, sphingomyelinase in Niemann-Pick disease, and ceramidetrihexosidase in Fabry’s disease(1).

Keywords

Sialic Acid Lipid Storage Disease Sachs Disease Human Muscle Tissue Hexosaminidase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brady, R. O. Cerebral lipidoses. Ann. Rev. Med. 21, 317 (1970).PubMedCrossRefGoogle Scholar
  2. 2.
    Brady, R. O. The sphingolipidoses. New Eng. J. Med., 275, 312 (1966).PubMedCrossRefGoogle Scholar
  3. 3.
    Sandhoff, K., Andreae, U., and Jatzkewitz, H. Deficient hexosaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs. Life Sci., 7, 283 (1968).PubMedCrossRefGoogle Scholar
  4. 4.
    Kolodny, E. H., Brady, R. O., Quirk, J. M., and Kanfer, J. N. Preparation of radioactive Tay-Sachs ganglioside labeled in the sialic acid moiety. J. Lipid Res., 11, 144 (1970).PubMedGoogle Scholar
  5. 5.
    Kolodny, E. H., Kanfer, J. N., Quirk, J. M., and Brady, R. O. Properties of a particle-bound enzyme from rat intestine that cleaves sialic acid from Tay-Sachs ganglioside. J. Biol. Chem., 246, 1426 (1971).PubMedGoogle Scholar
  6. 6.
    Kolodny, E. H., Brady, R. O., Quirk, J. M., and Kanfer, J. N. Studies on the metabolism of Tay-Sachs ganglioside. Federation Proc., 28, 596 (1969).Google Scholar
  7. 7.
    Kolodny, E. H., Brady, R. O., and Volk, B. W. Demonstration of an alteration of ganglioside metabolism in Tay-Sachs disease. Biochem. Biophys. Res. Commun., 37, 526 (1969).PubMedCrossRefGoogle Scholar
  8. 8.
    Tallman, J. F., Brady, R. O., and Johnson, W. G. Manuscript in preparation.Google Scholar
  9. 9.
    Quirk, J. M., Tallman, J. F., and Brady, R. O. The preparation of trihexosyl-and tetrahexosylgangliosides specifically labeled in the N-acetylgalactosaminyl moiety. J. Labeled Compounds, in press.Google Scholar
  10. 10.
    Okada, S., and O’Brien, J. S. Tay-Sachs disease: generalized absence of a beta-D-N-acetylhexosaminidase component. Science, 165, 698 (1969).PubMedCrossRefGoogle Scholar
  11. 11.
    Brady, R. O., O’Brien, J. S., Bradley, R. M., and Gal, A. E. Sphingolipid hydrolases in brain tissue of patients with generalized gangliosidoses. Biochim. Biophys. Acta, 210, 193 (1970).PubMedCrossRefGoogle Scholar
  12. 12.
    Kampine, J. P., Kanfer, J. N., Gal, A. E., Bradley, R. M., and Brady, R. O. Response of sphingolipid hydrolases in spleen and liver to increased erythrocytorrhexis. Biochim. Biophys. Acta, 137, 135 (1967).PubMedCrossRefGoogle Scholar
  13. 13.
    Suzuki, Y., Jacob, J. C., Suzuki, K., Kutty, K. M., and Suzuki, K.GM2 gangliosidosis with total hexosaminidase deficiency. Neuro ogy, 21, 313 (1971).Google Scholar
  14. 14.
    Frohwein, Y. Z., and Gatt, S. Enzymatic hydrolysis of sphingolipids. VI. Hydrolysis of ceramide glycosides by calf brain ß-N-acetylhexosaminidase. Biochemistry, 6, 2783 (1967).PubMedCrossRefGoogle Scholar
  15. 15.
    Johnson, W. G., and Brady, R. O. Purification of hexosaminidase A. in S. P. Colowick and N. O. Kaplan (Eds.) Methods in Enzymology, Academic Press, N. Y., in press, 1972.Google Scholar
  16. 16.
    Rapoport, S. I., Hori, M., and Klatzo, I. Reversible osmotic opening of the blood brain barrier. Science, 173, 1026 (1971).PubMedCrossRefGoogle Scholar
  17. 17.
    Merril, C. R., Geier, M., and Petricciani, J. C. Bacterial virus gene expression in human cells. Nature, 233, 398 (1971).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1972

Authors and Affiliations

  • R. O. Brady
    • 1
    • 2
  • J. F. Tallman
    • 1
    • 2
  • W. G. Johnson
    • 1
    • 2
  • J. M. Quirk
    • 1
    • 2
  1. 1.Lab. of NeurochemistryNINDS, NIHBethesdaUSA
  2. 2.Dept. of Biochem.Georgetown Univ.USA

Personalised recommendations